Updated 2/14/09

CURRICULUM VITAE

Jerald Patrick Radich, M.D.

Personal

Birth:	October 30, 1954, Sonoma, California
Married:	Dorcas Dobie, M.D.
Children:	Quinn Patrick Emma Elizabeth
Home:	26327 SE 33rd St. Sammamish, WA 98075 Tele: 425-557-6475
Work:	Fred Hutchinson Cancer Research Center 1100 Fairview Ave. N., D4-100 Seattle, WA 98109 Tele: 206-667-4118 FAX: 206-667-2917 email: jradich@.fhcrc.org

Education

1972-1976	University of California, San Diego: B.A. (Biology) with Honors
1976-1977	University of California, San Diego: Postgraduate studies (Biology)
1977-1979	Harvard University School of Public Health: M.S. (Epidemiology)
1979-1983	University of California School of Medicine, Davis: M.D.

Postgraduate training

1983-1984	University of Washington Affiliated Hospitals: *Internship* in Internal Medicine
1984-1986	University of Washington Affiliated Hospitals: *Residency* in Internal Medicine
1986-1987	Veterans Administration Medical Center Affiliated Hospitals, Seattle, WA: *Chief Medical Resident*
1987-1990	University of Washington and the Fred Hutchinson Cancer Research Center: *Fellowship* in Medical Oncology

Positions held

1986-1987	Chief Medical Resident, V.A. Hospital, Seattle
1990-1993	Associate in Clinical Research, Fred Hutchinson Cancer Research Center
1993-1998	Assistant Member, FHCRC; Assistant Professor, University Washington School of Medicine

1998-	Associate Member, FHCRC; Associate Professor, University Washington School of Medicine
2003-	Member, FHCRC
2004-	Professor, University of Washington School of Medicine
2003-	Medical Director, Research Trials Office, FHCRC/Seattle Cancer Care Alliance
2004-	Director, Southwest Oncology Group (SWOG) lymphoid and chronic myeloid leukemia Repository

License and Certification

1984-	State of Washington Medical License 252-09 0021791
1986-	Board certified, American Board of Internal Medicine
1989-	Board certified, Medical Oncology

Grants and awards

1991	American Cancer Society Physician Fellowship #PRTF-134: "The detection of minimal residual disease in acute myelogenous and acute lymphocytic leukemia." $22,000 direct costs/year.
1991-1994	Leukemia Society of America Fellowship Award: "The detection of minimal residual disease in acute lymphocytic leukemia." 12/90-12/93. $75,000 direct cost.
1991-1994	NIH Clinical Investigator Award K08 CA01612: "The detection of minimal residual disease in acute leukemia." 9/91-9/94. $211,905 direct costs/year.
1991-1996	NIH CA 18029: Project 7, Adult Leukemia Center grant. "The detection of minimal residual disease." $177,977 direct costs/year.
1993-1997	NIH 1U01 CA60432: "Hypothesis driven clinical correlations in hematologic malignancies." $20,013 direct costs/year.
1995-1996	NIH CA66186-01: Pilot project: "Evaluation of immunity to the HER-2/NEU oncogeneic protein in patients with breast cancer." $40,500 direct costs/year.
1996-1998	NIH CA 32102: "Stem cell sorting and leukemogenesis in adult ALL." $19, 309 direct costs/year.
1997-2002	NIH CA 18029: Project 6, Adult Leukemia Center grant. "Detection and treatment of minimal residual disease." $199,871 direct costs/year.
1999-2004	NIH CA85053: "Gene expression profile of progression and response in CML." $217, 873 direct costs/year.
2001-2006	NIH CA 18029: Project 6, Adult Leukemia Center grant. “Discovery and validation of genetics markers of prognosis and minimal residual disease.” $175,902 direct costs/year.

2003-2008	NIH CA 103728: "Seattle Cancer and Aging Program." $77,793 direct costs/year.
2004-2009	NIH/NCI via SWOG: "SWOG Lymphoid Leukemia Disease Reference Laboratory." $123,865 direct costs/year.
2005-2009	NIH HL 83050: "Abnormalities in Gene Expression in Therapy Related MDS." $77,579 direct costs/year.
2005-2010	NIH CA 114762: "Strategic Partnering to Evaluate Cancer Signatures." $150,237 direct costs/year.
2005-2010	Leukemia and Lymphoma Foundation: "Specialized Center of Research in Acute Leukemia: From Comprehensive Molecular Technologies to Improve Risk Classification and Therapy." $95,833 direct costs/year.
2006-2011	NIH CA 18029: Project 4, Adult Leukemia Center grant. "Resistance and relapse in CML." $175,902 direct costs/year.

Honors and professional societies

1972-1976	Dean's Honor List (x7), University of California, San Diego
1977-1979	Exxon Fellowship for Epidemiology Research and Training, Harvard University
1979	Betty Lea Stone Fellowship, American Cancer Society, Harvard University
1982	Alpha Omega Alpha (as third year medical student), University of California, Davis
1983	Commencement speaker (medical school commencement), University of California, Davis
1983	Phi Kappa Phi Honor Society, University of California, Davis
1992-	Member, American Association for Cancer Research
1995-	Member, Society of Blood and Marrow Transplantation
1997-	Member, American Society of Hematology
2008-	Fellow, American College of Physicians

Professional Committees

1994-	Leukemia Biology Committee, Southwest Oncology Group
1994-	Bone Marrow Transplant Committee, Southwest Oncology Group
1994-1997	Appointments and Promotions, FHCRC
1995-	Institutional Review Board, FHCRC
1995-1999	Planning Committee, Seattle Breast Cancer Research Program
1997-	Associate Program Head, Marrow Transplantation, FHCRC
1997-1999	Clinical Staffing Task Force, FHCRC
1997-1999	Patient Care Delivery Steering Committee, FHCRC
1998-	Chairman, Clinical Investigation Meeting, FHCRC
1999-	Scientific Strategy Subcommittee, FHCRC

2000-	Clinical Trials Management Committee, FHCRC
2000-	Pediatric Solid Tumor Search Committee, FHCRC
2000-2002	Member Needs and Future Initiatives, ASBMT
2000-	National Comprehensive Cancer Committee, CML
2000-2002	Associate Program Head, Genetics and Genomics, FHCRC
2001-	Clinical Research Investigator Committee, FHCRC/UW
2004-	SBIR Study Section, NIH
2005-	US Army Medical Research CML Integration Panel
2006-	Chair, USAMR CML Integration Panel
2007-	Contributing Editor, *The Hematologist*
2008-	Editorial Board, *Haematologica*
2007-	External Advisory Board, MD Anderson MDS Program Project
2008-	Chair, Novartis CML Correlation Sciences Group

Bibliography

Peer Reviewed Original Work

1. Meyers FJ, Cardiff RD, Taylor C, Zuniga M, **Radich JP**. Hairy cell leukemia has a B-cell genotype. Hematol. Oncol. 2: 145-150, 1984

2. Collins SJ, Howard M, Andrews DF, Agura E, **Radich J**. Rare occurrence of N-*ras* point mutations in chronic myeloid leukemia. Blood 73: 1028-1032, 1989

3. **Radich JP**, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F, Collins SJ. N-*ras* mutations in adult *de novo* acute myelogenous leukemia: prevalence and clinical significance. Blood 76: 801-807, 1990

4. **Radich JP**, Kopecky KJ, Appelbaum FR, Willman CL, Collins SJ. N-*ras* mutations in acute myleogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group Experience. Leukemia and Lymphoma 6: 325-334, 1992

5. **Radich JR**, Sanders JE, Buckner CD, Martin PJ, Peterson FB, Bensinger W, McDonald GB, Mori M, Schoch G, Hansen JA. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J. Clin. Onc. 11: 304-313, 1993

6. Hromas R, **Radich J**, Collins S. PCR cloning of an orphan homeobox gene (PRH) preferentially expressed in myeloid and liver cells. Biochem. Biophys. Res. Comm. 195: 976-983, 1993

7. **Radich JP**, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, Kirk J, Lee A, Kessler P, Appelbaum F, Gehly G. Detection of *bcr-abl* fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 8: 1688-1695, 1994

8. Edmands S, Kirk J, Lee A, **Radich J**. Rapid RT-PCR amplification from limited cell numbers. PCR Methods and Applications 3: 317-319, 1994

9. Appelbaum FR, Clift R, Buckner CD, Anasetti C, **Radich J**, Higano T, Storb R, Hansen J, Thomas ED. Allogeneic marrow transplantation for chronic myeloid leukemia. Medical Oncology 11: 69-74, 1994

10. Boldt DH, Kopecky KJ, Head D, Gehly G, **Radich JP**, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group Experience. Leukemia 8: 2118-2126, 1994

11. Lee A, Kirk J, Edmands S, **Radich J**. Multiplex PCR of *bcr-abl* fusion transcripts in Philadelphia positive acute lymphoblastic leukemia. PCR Methods and Applications 4: 283-287, 1995

12. **Radich JP**, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED. PCR detection of the *bcr-abl* fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 85: 2632-2638, 1995

13. Kirk JA, Reems JA, Roecklin BA, VanDevanter DR, Bryant EM, **Radich J**, Edmands S, Lee A, Torok-Storb B. Benign marrow progenitors are enriched in the $CD34^{+}$/HLA-DR^{lo} population but not in the $CD34^{+}/CD38^{lo}$ population in chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybridization. Blood 86: 737-743, 1995

14. **Radich J**, Ladne P, Gooley T. PCR-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation 1: 24-31, 1995

15. Kirk JA, **Radich J**, Edmands S, Lee A, VanDevanter DR, Reems, JA, Bryant EM. Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia. American Journal of Hematology 52: 129-134, 1996

16. Horwitz MS, Sabath DE, Smithson WA, **Radich J**. A family inheriting different subtypes of acute myelogenous leukemia. American Journal of Hematology 52: 295-304, 1996

17. Tsai T, Davalath S, Rankin C, **Radich JP**, Head D, Appelbaum FR, Boldt DH. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies. Leukemia 10: 1901-1910, 1996

18. **Radich J**, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, Appelbaum FR. The detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 89: 2602-2609, 1997

19. Slattery JT, Clift RA, Buckner CD, **Radich J**, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 89: 3055-3060, 1997

20. Sierra J, **Radich J**, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, Bryant E, Nash RA, Sanders JE, Storb R, Sullivan KM, Appelbaum FR, Anasetti C. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90: 1410-1414, 1997

21. Higano CS, Chielens D, Raskind W, Bryant E, Flowers MED, **Radich J**, Clift R, Appelbaum F. Use of alfa-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 90: 2549-2554, 1997

22. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, **Radich J**, Sanders JE, Storb RF, Sullivan KM, Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. NEJM 338: 962-968, 1998

23. Rowley SD, Loken M, **Radich J**, Kunkle LA, Mills BJ, Gooley T, Holmberg L, McSweeney P, Beach K, MacLeod B, Appelbaum F, Bensinger WI. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplantation 21: 1253-1262, 1998

24. Banker DE, **Radich J**, Becker A, Kerkof K, Norwood T, Willman C, Appelbaum FR. The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 4: 3051-3062, 1998

25. Stirewalt, D.L., Clurman, B., Appelbaum, F.R., Willman, C.L., Radich, J.P. P73 mutations and expression in adult *de novo* acute myelogenous leukemia. Leukemia 13: 985-990, 1999

26. Thomson B, Hawkins D, Felgenhauer J, **Radich J**. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma. Bone Marrow Transplantation 24: 527-533, 1999

27. Bodó I, Peters M, **Radich JP**, Hess J, Blinder M, Watson MS, Van Rheeden R, Natarajan S, Lowell JA, Brown R, DiPersio J, Adkins D. Donor-derived acute promyleocytic leukemia in a liver transplant recipient. NEJM 341: 807-813, 1999

28. Clift RA, **Radich J**, Appelbaum FR, Martin P, Flowers MED, Deeg HJ, Storb R, Thomas ED. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan andcyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia (Letter to Editor). Blood 94: 3960-3962, 1999

29. Nelson RE, Wong L, **Radich J**. The effect of long-term freezing of RT-PCR reagent mixes on the sensitivity of bcr-abl mRNA detection (Letter to Editor). Leukemia 13: 1299-1300, 1999

30. **Radich JP**, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biology of Blood and Marrow Transplantation 6: 272-279, 2000

31. Flowers MED, Leisenring W, Beach K, Riddell S, **Radich JP**, Higano C, Rowley SD, Chauncey TR, Bensinger WI, Sanders JE, Anasetti C, Storb R, Wade J, Appelbaum FR, Martin PJ. G-CSF given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biology of Blood and Marrow Transplantation 6: 321-326, 2000

32. Stirewalt D, **Radich J**. Tumor suppressor alterations in acute myeloid leukemia. Hematology 5: 15-25, 2000

33. Stock W, Tsai T, Golden C, Rankin C, Sher D, Slovak ML, Pallavicini MG, **Radich JP**, Boldt DH. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood 95: 2364-2371, 2000

34. **Radich JP**. The detection and significance of minimal residual disease in chronic myeloid leukemia. Medicina 60: 66-70, 2000

35. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, **Radich JP**. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97: 89-94, 2001

36. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, **Radich JP**, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers MED, Georges GE, Grumet FC, Kiem H-P, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400, 2001

37. Meshinchi S, Thomson B, Finn LS, Leisenring W, Green C, **Radich JP**, Loken M, Hawkins D. Comparison of multi-dimensional flow cytometry to standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia. Pediatric Hematology and Oncology 23: 585-590, 2001

38. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Willman CL, **Radich JP**. *FLT3*, *Ras*, and p53 Mutations in elderly patients with acute myeloid leukemia. Blood 97: 3589-3595, 2001

39. **Radich JP**, Gooley T, Bryant E, Chauncey T, Clift R, Edmands S, Flowers MED, Kerkof K, Nelson R, Wong L, Appelbaum FR. The significance of *bcr-abl* molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplant. Blood 98: 1701-1707, 2001

40. Stirewalt D, Willman CL, **Radich JP.** Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leukemia Research 25: 1085-1088, 2001

41. Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers MED, Hansen J, Martin PJ, Nash RA, Petersdorf E, **Radich J**, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR. Hemopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated TBI is associated with low relapse rate but considerable non-relapse mortality. Biology of Blood and Marrow Transplantation 8: 161-169, 2002

42. **Radich JP**. The promise of gene expression analysis in hematopoetic malignancies. Biochimica et Biophysica Acta 1602: 88-95, 2002

43. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PF, Petersdorf E, **Radich JP**, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Brant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR. Conditioning with targeted busulfan and cyclophosphamide for hemopoeitic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100: 1201-1207, 2002

44. Platzbecker U, Gooley T, Anasetti C, Appelbaum FR, Clurman B, Doney K, Chauncey T, Flowers MED, Myerson D, **Radich JP**, Storb R, Witherspoon RP, Deeg HJ.

Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leukemia and lymphoma, 43: 1409-1414, 2002.

45. **Radich JP**, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, Martin P, Slattery J, Sultan D, Appelbaum FR. HLA-matched related hematopoetic cell transplantation for CML chronic phase using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102: 31-35, 2003

46. Stirewalt DL, Guthrie KA, Beppu L, Bryant E, Doney K, Gooley T, Appelbaum FR, **Radich JP**. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biology of Blood and Marrow Transplantation 9: 206-212, 2003

47. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Martin PJ, Mc Donald GB, Nichols WG, **Radich JP**, Woolfrey A, Jenke A, Schleyer E, Thiede C, Ehninger G, Anasetti C. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102: 820-826, 2003

48. Meshinchi S, Stirewalt DL, Alanzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, **Radich JP**. Activating mutations of RTK/*ras* signal transduction pathway in pediatric acute myeloid leukemia. Blood 102: 1474-1479, 2003

49. Zwaan CM, Meshinchi S, **Radich JP**, Veerman AJP, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R, Zimmermann M, Reinhadt D, Harbott J, Creutzig U, Kaspers GJL, Griesinger F. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance. Blood 102: 2387-2394, 2003

50. O'Brien SM, Kantarjian H, **Radich JP**. Update: Chronic myelogenous leukemia clinical practice guidelines. JNCCN [Suppl 1]S-29-S-40, 2003

51. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, **Radich JP**, Anderson G, Hartwell L. The case for early detection. Nature Reviews/Cancer 3:1-11, 2003

52. O'Brien S, Berman E, Copelan E, Emanuel PD, Erba HP, Greenberg PL, Pavletic SZ, **Radich JP**, Saba HI, Schilder R, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M. Chronic myelogenous leukemia. JNCCN [Suppl 1]S-14-S-28, 2003

53. Johnston DL, Meshinchi S, Opheim KE, Pallavicini MG, Feusner J, Woods WG, Lange BJ, **Radich JP**, Bernstein ID. Stem cell involvement is predictive of response to induction chemotherapy in acute myeloid leukemia. Br J Haemat 123: 431-435, 2003

54. Stirewalt DL, **Radich JP**. The role of FLT3 in haematopoetic malignancies. Nature Reviews/Cancer 3: 650-665, 2003

55. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochaus A, Hensley ML, Gathmann I, Bolto AE, van Hoomissen IC, Goldman JM, **Radich JP**. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1421-1430, 2003

56. Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, **Radich JP**, Sanders JE. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biology of Blood and Marrow Transplant 9: 206-713, 2003

57. Deeg HJ, Gooley TA, Flowers MED, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, **Radich J**, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102: 3912-3918, 2003

58. Lampe JW, Stepaniants SB, Mao M, **Radich JP**, Dai H, Linsley PS, Friend SH, Potter JD. Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke. Cancer Epidemiology Biomarkers & Prevention 13: 445-453, 2004

59. Stirewalt DL Meshinchi S, Kussick SJ, Sheets, KM, Pogosova-Agadjanyan E, Willman CL, **Radich JP**. Novel *FLT3* Point Mutations within Exon 14 Found in Patients with Acute Myeloid Leukaemia. British Journal of Haematology 124: 481-484, 2004

60. Stirewalt DL, Pogasova E, Khalid N, Sala O, Ladne P, Harre D, Zhao LP, **Radich JP**. Single stranded linear amplification protocol (SLAP) reproducibly and reliably amplifies nanogram amounts of mRNA. Genomics 83: 321-331, 2004

61. **Radich JP**, Mao M, Stepaniants S, Biery M, Castle J, Ward T, Schimmack G, Kobayashi S, Carleton M, Lampe JL, Linsley P. Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics 86: 980-988, 2004

62. Bradfield SM, **Radich JP**, Loken MR. The graft-versus-leukemia effect in acute lymphoblastic leukemia: The importance of tumor burden and early detection by flow cytometry. Leukemia 18: 1156-1158, 2004

63. Kussick SJ, Stirewalt DL, Yi HS, Sheets KM, Pogosova-Agadjanyan E, Braswell S, Norwood TH, **Radich JP**, Wood BL. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 18: 1591-1598, 2004

64. Petersdorf EW, Anasetti C, Martin PJ, Gooley T, **Radich J**, Malkki M, Woolfrey A, Smith A, Mickelson E, Hansen JA. Limits of HLA Mismatching in Unrelated Hematopoietic Cell Transplantation. Blood 104: 2976-2980, 2004

65. Platzbecker U, Kurre P, Guardiola P, Ward JL, **Radich JP**, Kiem HP, Deeg HJ. Fanconi Anemia type C deficient hematopoetic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand) induced cleavage of pro-capase 8. Experimental Hematology 32: 815-821, 2004

66. Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, **Radich JP**. Elevated expression of the AF1Q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104: 3058-3063, 2004

67. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, **Radich JP**, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104: 2646-2654, 2004

68. Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B, Potter JD, **Radich JP**. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin. Cancer Res.

10: 7592-7598, 2004.

69. Haddad R, Guardiola P, Izac B, Thibodeau C, **Radich J**, Delezoide A-L, Baillou C, Lemoine FM, Gluckman JC, Pflumio F, Canque B. Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood. Blood 104: 3918-3926, 2004.

70. Tse W, Deeg HJ, Stirewalt D, Appelbaum FR, **Radich J**, Gooley T. Increased AF1qgene expression in high-risk myelodysplastic syndrome. Br. J. Haematol. 128: 218-220, 2004.

71. Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA, **Radich JP**, Pulsipher MA, Agura ED, Chauncey TR, Maloney DG, Shizuru JA, Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 11: 272-279, 2005.

72. Oehler,VG, **Radich JP**, Storer B, Blume KG, Chauncey T, Clift R, Snyder DS, Forman SJ, Flowers MED, Martin P, Guthrie KA, Negrin RS, Appelbaum FR, Bensinger W. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 11: 85-92, 2005.

73. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, **Radich JP**, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19:990-997, 2005.

74. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, **Radich JP**, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23: 3819-3829, 2005.

75. O'Brien S, Berman E, Bhalla K, Copelan EA, Develtten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorak, D, **Radich JP**, et al. Chronic myelogenous leukemia. J Natl Compr Canc Netw, 3:732-755, 2005.

76. **Radich JP**. Impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 90: 1442, 2005.

77. **Radich JP,** Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah C, Stock W, Willman C, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. PNAS 103: 2794-2799, 2006.

78. Stirewalt DL, Kopecky KJ, Meshinchi S. Engel JL,.Pogosova-Agadjanyan EL, Linsley J. Slovak ML, Willman CL, **Radich JP**. Size of FLT3 Internal Tandem Duplication has Prognostic Significance in Patients with Acute Myeloid Leukemia. Blood 107: 3724-3726, 2006

79. Sala-Torra O, Hanna C, Loken MR, Flowers MED, Maris M, Ladne PA, Mason JR, Senitzer D, Rodriguez R, Forman SJ, Deeg HJ, **Radich JP**. Evidence of donor-derived hematological malignancies following hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplant 12: 511-517, 2006.

80. Hughes TP, Deininger MW, Hochhaus A, Branford S, **Radich JP**, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors-Review and recommendations for "harmonizing" curing methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28-37, 2006.

81. Deeg HJ, Storer BE, Boechk M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Keim HP, Nash RA, O'Donnell PV, **Radich JP**, Sandmaier BM, Scott BL, Sorrow ML, Warren EJ, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Reduced acute and chronic GVHD with the addition of thymoglobulin to a targeted busulfan/cyclosphosphamide regimen. BIol Blood Marrow Transplant: 12: 573-584, 2006.

82. Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, **Radich JP**, Bernstein ID, Meshinchi S. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood 108:2764-2769, 2006.

83. Wilson CS, Davidson GS,Martin SB, Andreies E, Petter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker J, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, **Radich JP**, Appelbaum FR, Atlas SR, Godwin J, WIllman CL. Gene expression profiling of adult acute myeloid leukemia reveals novel biologic clusters for risk classification and outcome prediction. Blood 108:685-696, 2006

84. Branford S, Cross NCP, Hochhaus A, **Radich J**, Saglio G, Kaeda J, Goldman J, Hughes T. Rationale for the proposed recommendations for harmonizing current methodology for detecting *BCR-ABL* transcripts and for expressing results on an International Scale. Leukemia 20:1925-1930, 2006.

85. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJL, Heerema NA, Gerbing R, Lange BJ, **Radich JP**. Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654-3661, 2006

86. Druker BJ, Guilot F, O'Bijren SG, …**Radich JP**. …Larson RA. Five-year follow-up of imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic phase. New Engl. Journal of Medicine,355: 2408-2417, 2006

87. Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, **Radich JP**, Alonzo TA. The role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 108: 400, 2006

88. Appelbaum FR, Rosenblum D, Arceci R, Carroll WL, Breitfeld FP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, **Radich J**, Scher NS, Smith FO, Stone RM, Tallman MS. Endpoints to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109: 1810-1816, 2007

89. O'Brien S, **Radich JP,** et al. Chronic myelogenous leukemia. J Natl Compr Canc Network. 5: 474-496. 2007.

90. **Radich JP**, Oehler V. Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors. J Natl Compr Canc Network. 5: 497-504. 2007.

91. Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, **Radich JP**. Connective tissue growth

factor (CTGF) expression correlates with outcome in adult patients with acute lymphoblastic leukemia (ALL) treated with conventional chemotherapy. Blood109: 3080-3083, 2007

92. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Scotnicki A, Hellman A, Zaritsky A, Golenkov A, **Radich J**, Hughes T, Dejardin D, Countouriiotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line iimatinib: a randomized phase-II trial. Blood 109: 5143-5150, 2007

93. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, Appelbaum FR, **Radich JP**. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109:2791-2793, 2007

94. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cumings CC, Chu S, Bhatia R, Forman SJ, Negrin RS, Appelbaum FR, **Radich JP**. The effects of imatinib mesylate treatment before allogeneic transplant for chronic myeloid leukemia. Blood. 109:1782-1789, 2007.

95. Winn-Deen ES, Helton B, Van Atta R,…**Radich JP**. Development of an integrated assay for detection of Bcr-Abl RNA. Clinical Chemistry 53: 1593-1600, 2007

96. Oehler V, **Radich JP**. Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy. Clinical Lymphoma and Myeloma 7:S58-63, 2007

97. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G. **Radich J**, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309-2315, 2007

98. **Radich JP**, Oehler V. Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors. J Natl Compr Cancer Network 5:497-504, 2007.

99. Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, **Radich JP**, Deeg HJ. TNF induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? British J Haematology, 140: 444-453, 2008

100. Le Coutre P, Ottmann OG, Giles F,…**Radich JP**, Zheng M, Soou Y, Kantarjian H. Nilotiinb (formerly AMN107), a highly selective e BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resitant or -intolerant accelerated phase chronic myelogenous leukemia. Blood 111: 1834-1839, 2008.

101. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engle JH, Cronk MR, Shannon-Dorcy K, McQuary AR, Hockenbery D, Wood B, Heimfeld S, **Radich JP**. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes, Chromosomes, Cancer 47:8-20, 2008

102. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, **Radich J**, Ottmann O, Cortes J. Optimized outcomes for patients with advanced disease in chronic myelogeous leukemia. Seminar in Oncology, 35: S1-15, 2008

103. **Radich JP**. Optimizing timing of secondary tyrosine kinase therapy in chronic myeloid leukemia. Clinical Lymphoma and Myeloma 8:577-586, 2008

104. Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RZB, Rocnik JL, Lange BJ, Gilliland DG, **Radich JP**. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 111: 4930-4933, 2008

105. Rosinski KV, Fujii N, Mito JK, Koo KKWK, Xuereb SM, Sala-Torra O, Gibbs JL, **Radich JP**, AKAtsuka Y, Van den Eynde BJ, Riddell SR, Warren EH. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemia stem cells. Blood 111:4817-4826, 2008

106. Bar M, Deeg J, Stirewalt D, Bhatia R, **Radich J**. Gene expression changes in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. Translational Oncogenomics, in press, 2008

107. **Radich, J**. Effect of time to major molecular response on survival: Testing in community practice. Clinical Leukemia 2:21-247, 2008

108. Oehler V, Qin J, Ramakrishnan Facer RG, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, **Radich J**. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 23:396-369, 2008

109. Bar M, Wylman SK, Fritz BR, Qi J, Garg KS, Parkin RK, Kroh EM, Bendoraite A, Mitchell PS, Nelson A, Ruzzo WL, Ware C, **Radich JP**, Gengleman R, Ruohola-Baker H, Twewari M. Micro RNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells 26:2496-2505, 2008

110. Stirewalt DL, Choi YE, Sharpless NE, Pogosova-Agadjanyan E, Cronk MR, Yukawa M, Larson EB, Wood BL, Appelbaum FR, **Radich JP**, Heimfeld S. Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells. Leukemia 23:391-393, 2008

111. Cross NCP, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, **Radich J**, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM. BCR-ABL-positive CML and BCR-ABL-negative myeloproliferative disorders – some common and some contrasting features. Leukemia, in press, 2008

112. Branford S, Fletcher L, Cross NCP, Muller MC, Hochhaus A, Kim DW, **Radich JP,** Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T. Desirable performance characteristics for *BCR-ABL* measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trails Blood 112:3330-3338, 2008

113. Cortes J, Kim D-W, Raffoux E, Martinelli g, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang J-L, Hochhaus A, Khoury HJ, Brummerndort TH, Michalelet M, Rege-Cambrin G, Gambacorti-Passerieni**, Radich JP**, Ernst T, Zhu C, Van Tornout JMA, Talpaz M. Efficacy and safety of dasatinib in imatinib-resistant or –intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22: 2176-2183, 2008

114. Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, **Radich JP**, Hochhaus A. Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in

Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP). In press, JCO

115. Ho P, Alonzo T, Gerbing R, Pollard J, Stirewalt D, Hurwitz C, Heerema N, Hirsch B, Raimondi S, Lange B, Franklin J, **Radich J**, Meshinch S. Prevalence and prognostic implications of CEBPA mutations in pediatric AML: a report from the Children's Oncology Group. In press, Blood

116. Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, **Radich JP**, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Phase III study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood, *in pres*s, 2009.

Invited Editorials and Reviews

1. **Radich JP**, Kopecky KJ, Appelbaum F, Willman CL, Collins SJ. N-*ras* mutations in acute myelogenous leukemia: a review of the current literature and an update of the Southwest Oncology Group experience. Leukemia and Lymphoma 6: 325, 1992

2. **Radich JP**. Minimal residual disease. Current Opinion in Hematology, 2: 300-304, 1995

3. **Radich J.** Gene quantification now. Molecular Medicine Today, 2: 228-229, 1996

4. **Radich J.** The promise of gene quantification. Trends in Biotechnology, 14: 145-147, 1996

5. **Radich J.** Detection of minimal residual disease in acute and chronic leukemias. Current Opinion in Hematology 3: 310-314, 1996

6. **Radich J**, Thomson B. Advances in the detection of minimal residual disease (Review). Current Opinion in Hematology 4: 242-247, 1997

7. **Radich JP**. The use of PCR technology for detecting minimal residual disease in patients with leukemia. Reviews in Immunogenetics 1: 141-154, 1999

8. Sievers EL, **Radich JP**. Detection of minimal residual disease in acute leukemia. Current Opinion in Hematology 7: 212-216, 2000

9. **Radich J.** Clinical applicability of evaluation of minimal residual disease in acute leukemia. Current Opinion in Oncology 12: 36-40, 2000

10. **Radich JP**, Sievers E. New developments in the treatment of acute myeloid leukemia. Oncology 14: 125-131, 2000

11. **Radich JP.** Philadelphia chromosome-positive ALL. Hematology/Oncology Clinics of North America 15: 21-36, 2001

12. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers MED, **Radich J**, Little M-T, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem H-P, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Non-myeloablative hematopoietic cell transplantation: replacing high-dose cytotoxic therapy by the graft versus tumor effect. Ann NY Acad Sci 938: 328-337, 2001

13. **Radich JP**. Molecular targets in AML. Hematology 2001: American Society of Hematology Education Book, 68-73, 2001

14. **Radich JP.** Transplant approaches in CML. Hematology 2002: American Society of Hematology Education Book, 124-130, 2002

15. Stirewalt DL, Meschinchi S, **Radich JP.** Molecular targets in acute myelogenous leukemia. Blood Reviews 17: 15-23, 2002

16. Oehler VG**, Radich JP**. Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. Current Oncology Reports 5: 426-435, 2003

17. **Radich JP**, Olavarria E, Apperley JF. Allogeneic transplantation for CML. Hematology/Oncology Clinics of North America 18: 685-703, 2004

18. **Radich, JP**. Targeting ALL leukemia. Blood 104: 1235-1236, 2004

19. Sala O**, Radich JP**. Philadelphia chromosome positive ALL. Hematological/Oncology Clinics of North America, *in press*

20. Oehler VG**, Radich JP**. Monitoring *bcr-abl* by polymerase chain reaction in the treatment of chronic myeloid leukemia. Current Oncology Reports, *in press*

21. Bellido M, Stirewalt DL, Zhao LP, **Radich JP**. Use if gene expression microarrays for the study of acute leukemia. Expert Review of Molecular Diagnostics 6: 733-747, 2006.

22. **Radich J**. Commentary: Early allogeneic transplantation for chronic myelogenous leukemia in the imatinib era: A preliminary assessment. Blood Cells, Molecules, & Diseases 37: 125-127, 2006

23. Chung N-G, Buxhofer-Ausch V, **Radich JP**. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens 68: 371-375, 2006

24. **Radich J**. Practical guidelines for chronic myeloid leukemia response assessment. Clin Adv Hematology/Oncology, in press, 2007

25. **Radich JP.** The biology of blast crisis. ASH Education Program. 84-391, 2007

26. **Radich JP**. Is transplantation for CML dead? The Hematologist, Sept-Oct. 2007

27. **Radich JP**. The wasteland of relapsed adult ALL. The Hematologist March-April 2008

28. **Radich JP**. Solving the mysteries of myelodyplasia. PLOS Medicine, 2008, in press.

29. **Radich JP**. The molecular classification of acute myeloid leukemia: Are we there yet? JCO 26:4539-4540, 2008

30. **Radich JP.** Resistance is not futile. The Hematologist, 2009

Other Publications

1. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Bearman S, Erickson K, Flowers M, Hansen JA, Loughran T, Martin P, Matthews D, Petersdorf E, **Radich J**, Riddell S, Rovira D, Sanders J, Schuening F, Siadak M, Storb R, Witherspoon RP. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Seminars in Hemat. 28:250-259, 1991

2. Appelbaum FR, Clift R, **Radich J**, Anasetti C, Buckner CD. Bone marrow transplantation for chronic myelogenous leukemia (Review). Seminars in Oncology 22:405-411, 1995

3. Hansen JA, **Radich** JP, Petersdorf E, Martin PJ, Anasetti C. Retransplantation of marrow and hematopoietic stem cells from normal donors. In: Retransplantation, Proceedings of the 29th Conference on Transplantation and Clinical Immunology, 9-11 June, 1997. Touraine JL, Traeger J, Bétuel H, Dubernard JM, Revillard JP, and Dupuy C. (eds.). Netherlands: Kluwer Academic Publishers, Chapter 3:17-23, 1997

4. **Radich J**: The detection and quantification of *BCR-ABL* in chronic myeloid leukemia following marrow transplantation. In: Gene Quantification, Ferre F (ed.). Boston, MA: Birkauser, 1999.

5. **Radich J**: Multiplex polymerase chain reaction. In: The Nucleic Acid Protocols Handbook, Rapley R (ed.). Totowa, NJ: Humana Press, Inc., Chapter 78: 1999

6. **Radich JP**, Slovak ML: The laboratory evaluation of minimal residual disease. In: Hematopoietic Cell Transplantation, 2nd Edition, Thomas ED, Blume, KG and Forman SJ (eds.). Boston: Blackwell Science, Chapter 23: 235-247, 1999

7. **Radich JP**. Minimal residual disease. In: Encyclopedia Reference of Cancer, Schwab M. (ed.). Springer-Verlag, New York, NY, 2001

8. **Radich JP**. Minimal residual disease in allogeneic recipients. In: Allogeneic Stem Cell Transplantation. Lazarus H, Laughlin MJ (eds.).Humana Press, Tottowa, NJ, 2001.

9. **Radich JP**. MRD in Philadelphia-positive ALL. In: Minimal Residual Disease in Haematological Disorders; Bailliere's Clinical Haematology. Foroni, Hoffbrand (eds.). Bailliere's, London, UK, 2001.

10. **Radich JP**, Slovak ML: The laboratory evaluation of minimal residual disease. In: Hematopoietic Cell Transplantation, 3rd Edition, Thomas ED, Blume, KG and Forman SJ (eds.). Boston: Blackwell Science, Chapter 23: 235-247, 2004

11. **Radich JP**. Minimal residual disease. In: Encyclopedia Reference of Cancer, Schwab M. (ed.). Springer-Verlag, New York, NY, 2007

12. **Radich JP**, Slovak ML: The laboratory evaluation of minimal residual disease. In: Hematopoietic Cell Transplantation, 4th Edition, Thomas ED, Blume, KG and Forman SJ (eds.). Boston: Blackwell Science, in press

13. **Radich JP**, Slovak ML: Allogeneic and Autologous transplantation in chronic myeloid leukemia. In: Hematopoietic Cell Transplantation, 4th Edition, Thomas ED, Blume, KG and Forman SJ (eds.). Boston: Blackwell Science, in press.

Selected Invited Lectures (not including CME talks)

1995

Austrian Transplant Society Annual Meeting, Meran, Italy. "The detection and significance of *bcr-abl* after marrow transplantation."

Association of Molecular Pathology National Meeting, Minneapolis."The detection and significance of *bcr-abl* after marrow transplantation."

Association of Molecular Pathology National Meeting, Hematopathology Workshop. "Primer selction and other technical aspects of molecular testing for *bcr-abl*."

University of Florida, Hematology/Oncology Grand Rounds. "Minimal residual disease detection after marrow transplantation."

1996

Gene Quantification: Diagnosis, Monitoring and Drug Development, San Diego. "The detection and quantification of *bcr-abl* in chronic myeloid leukemia following marrow transplantation."

Children's Hospital Hematology/Oncology Grand Rounds, Los Angeles. "The detection of minimal residual disease in acute leukemia."

Gen-probe, San Diego, CA. "The detection and significance of *bcr-abl* after marrow transplantation."

Association of Blood and Marrow Transplantation National Meeting. "Minimal residual disease after transplantation."

Southwest Oncology Group National Meeting. " The study of residual disease in CML and ALL."

University of California, San Francisco Cancer Center Seminar Series. "The detection and significance of minimal residual disease post-transplantation."

Association of Molecular Pathology National Meeting. "The detection and significance of residual disease in ALL."

City of Hope Hematology Seminar Series. "Methodology and significance of residual disease detection."

1997

Fourth Biennial Oncology and Hematology Conference, Monterrey, CA. "Minimal residual disease."

New Perspectives in Oncology, Swedish Hospital, Seattle, WA. "Causes and Development of Cancer."

Cell Pro, Bothell, WA. "The detection and significance of minimal residual disease post-transplantation."

Hematology/Oncology Grand Rounds, Queen's Medical Center, Honolulu, HI. "The role of molecular biology in the detection of minimal residual disease."

1998

Association of Blood and Marrow Transplantation National Meeting. “The significance of minimal residual disease in Ph+ ALL.”

Puget Sound Oncology Consortium Cancer Genetics Symposium. “Utilizing molecular markers to identify minimal residual disease.”

Quest Diagnostics, San Juan Capistrano, Ca. “The detection and treatment of minimal residual disease in CML.”

University of Arizona Hematology/Oncology Grand Rounds. “Detection and significance of molecular relapse after transplantation.”

American Society of Hematology National Meeting. “Second allogeneic transplants after failure of initial autologous transplant.”

1999

Duke Sixth Annual Cancer Conference. “Minimal residual disease-do we treat?”

American Society for Blood and Marrow Transplantation National Meeting. “Detection and treatment of molecular relapse after transplantation for CML.”

Impath/Bis Pharmaceuticals. “Detection of minimal residual disease in CML-past, present, and future.”

University of Texas, San Antonio. “Detection and significance of minimal residual disease.”

American Association of Cancer Research Special Conference on Molecular Aspects of Metastasis. “Detection and significance of minimal residual disease in chronic myeloid leukemia.”

Fifth Biennial Oncology and Hematology Conference, Monterrey, CA. "Minimal residual disease."

American Society of Hematology National Meeting. “The significance of *bcr-abl* “molecular relapse” in CML patients $\geq$ 18 months post-transplant.”

2000

University of Chicago Hematology and Oncology Grand Rounds. “Detection and significance of minimal residual disease in chronic myeloid leukemia.”

NIH State of the Science in Acute Myelogenous Leukemia. “Signal transduction abnormalities in AML.”

National Cancer Care Network National Meeting. “New therapies in AML.”

Southwest Oncology Group National Meeting, Plenary Session. “Leukemia Genomics.”

2001

United States and Canadian Academy of Pathology Meeting. "Genome-based diagnostics."

American Society for Histocompatibility and Immunogenetics Education Workshop. "Minimal residual disease detection."

NIH Early Detection Research Network "Clinical applications of genomics of leukemia."

American Society of Hematology National Meeting, AML Education Session. "Molecular Targets in AML."

American Society of Hematology National Meeting. "Allogeneic transplantation for chronic phase CML using a targeted busulfan and cytoxan preparative regimen."

2002

National Cancer Care Alliance National Meeting. "CML treatment guidelines."

University of Nebraska, "Current treatment approaches in CML."

Spanish Bay Hematology and Oncology Conference. "Minimal residual disease: What does it mean/what should we do about it?"

Joint Grand Rounds, Tumor Boards, Spokane. "CML-past, present, future."

The University of Tokyo Symposium of Stem Cell and Hematopoesis. "New diagnostic and therapeutic targets in AML."

French Hematologic Society. "Evaluation of minimal residual disease."

Hospital Saint Louis, France, Special Lecture. "New developments in CML."

Leukemia/Lymphoma Society Regional Conference. "CML-past, present, future."

American Society of Hematology CML Education Session. "Transplant approaches in CML."

American Society of Hematology. "A randomized trial of peripheral blood versus bone marrow stem cell transplantation in CML."

New Concepts in CML, ASH "Super Friday." "Evolution of treatment in CML."

2003

Roswell Park Cancer Center, Grand Rounds. "New developments in the treatment and diagnosis of CML."

MD Anderson Cancer Center, Grand Rounds, "Molecular diagnostics in CML: Predicting relapse, progression, and response."

University of Alabama, Birmingham. "Signal transduction abnormalities in AML."

NIH State of the Science, acute lymphoblastic leukemia. "Minimal residual disease."

American Society of Clinical Oncology, Meet the Professor Series. “Genes and gene expression in cancer research.”

Mountain States Tumor Institute High Dose Therapy Conference. “CML treatment options and transplantation.”

Cleveland Clinic Grand Rounds. “CML: Past, present, and future.”

Case Western Reserve Blood Club: “CML: Past, present, and future.”

FASEB Conference on Hematologic Malignancies. “Update on signal transduction inhibition in CML.”

ESH International Conference on chronic myeloid leukemia. “Gene expression of prognosis and response in CML.”

Alta Bates Oncology and Hematology Biennial Conference. “Treatment of chronic myeloid leukemia: Monitoring of minimal residual disease.”

7th Congress of Brazilian Bone Marrow Transplantation Society.
“Treatment decisions in CML.”
“Molecular fingerprints in leukemia.”
“Molecular monitoring in CML.”

Red Cross Hospital, Koyoto, Japan. “Treatment decisions based on molecular monitoring in CML”

Strategy of ALL-Monitoring of Minimal Residual Disease Conference, Tokyo, Japan. “The influence of disease burden on outcomes of ALL following hematopoetic cell transplantation.”

NIH Director’s Challenge Conference. “Genetics of progression and response in CML.”

American Association of Hematology National Meeting. “Molecular Responses to Imatinib and Interferon + Ara-C in Newly Diagnosed CML: Efficacy of Imatinib on Patients After Cross-over from Interferon Therapy and Prognostic Importance of Molecular Responses on Long-Term Outcomes.”

2004

Leukemia and Lymphoma Society, Pittsburg. “Advances in bone marrow transplantation.”

Tandem Bone Marrow Transplant Meeting, Plenary session of CML. “Ablative allogeneic transplantation in CML.”

Rocky Mountain Cancer Institute. “Treatment decisions and molecular monitoring in CML.”

University of Colorado. “Molecular diagnostics and therapy decisions in leukemia.”

EORTC/NIH International Meeting on Molecular Markers. “Genetics of progression and response in chronic myeloid leukemia.”

Gen-Probe, San Diego. “New targets for molecular diagnostics.”

Lee Moffitt Cancer Center, Grand Rounds. “Genetics of progression and response in chronic myeloid leukemia.”

NIH Director’s Challenge Conference. “Gene expression and cancer: lesions from CML.”

2005

AACR Genetics and Cancer Symposium. “Genetics of progression in CML.”

Case Western University, Hematology/Oncology Grand Rounds. “CML: Treatment options and the role of molecular diagnostics.”

Alta Bates 8th Oncology and Hematology Conference. Treatment of CML: Monitoring of and treatment of minimal residual disease.”

NIH CML Consensus Workshop. “Novel mutation detection method.”

Cancer Vaccine Clinical Trials Workshop, Plenary Session. “Measuring residual disease burden.”

Association of Molecular Pathology Plenary Session. “Targeted therapies in CML.”

World Oncology Congress. “Diagnostics and monitoring in leukemia.”

Leukemia and Lymphoma Annual Research Symposium (ASH). “Molecular markers as guideposts and endpoints of therapy.”

ASH Meet the Professor. “Molecular monitoring in CML.”

2006

City of Hope Hematology/Oncology Grand Rounds. “CML, 2006: What now?”

International Congress on Hematologic Malignancies. “Bcr-Abl monitoring and transplantation in CML.”

Beckman Coltman Annual Scientific Symposium. “Molecular markers as guideposts and endpoints of therapy.”

National Cancer Care Alliance. “Role of transplantation in CML.”

Conference on Leukemia, Lymphoma, and Leukema. “Should patients stay on imatinib forever?”

Stanford Medical Center Medicine Grand Rounds. “Molecular diagnostics and treatment decisions in chronic myeloid leukemia.”

Oregon Health Sciences Universitiy. “Diagnosis and treatment of relapse post-transplant in Ph+ leukemia.”

ASH CML symposium. “Monitoring response and resistance in CML.”

2007

Memorial Sloan Kettering Cancer Center. “Molecular monitoring and treatment in CML.”

Keystone Tandem Transplant Meeting. “Refining treatment algorithms in CML.”

International Congress on Hematologic Malignancies. “Molecular monitoring in CML.”

National Cancer Care Network national meeting.
“Second line tyrosine kinase agents in CML.”
“The role of transplantation in CML.”
“NCCN guidelines for CML, 2007.”

University of Pennsylvania Institute of Translational Medicine and Therapeutics Conference on Personalized Medicine. “Individualized therapy in leukemia.”

Amgen/University of Washington Annual Research Symposium. “Genetics of response and progression in CML.”

Society of Biological Psychiatry Presidential Plenary Session. “Differential therapy in psychiatry: Lessons from Oncology.”

NIH Genome Initiative Grand Rounds. “Genetics of response and progression in CML.”

World Oncology Congress. “Monitoring in CML: When, how, and why.”

Rush/Loyola Annual Hematology/Oncology Conference. “Targeted therapy in acute leukemia: Promise or pipe dream?”

National Cancer Care Network Annual Hematological Oncology Meeting. “Update on primary and secondary therapy in CML.”

European School of Hematology International Conference on CML. “Regulation of progression and response in CML.”

CML in the Era to Tyrosine Kinase Inhibitors, ASH cooperate session. “Deciphering monitoring strategies in CML.”

American Society of Hematology CML Education Session. “Understanding progression in CML blast crisis.”

Second Global CML Workshop. “Response and progression in CML.”

2008

University of Nebraska. “CML 2008. What’s new?”

University of Washington Psychiatric Neuroscience. “Personalized medicine: promise or pipedream? Some lessons from oncology.”

International Congress on Hematologic Malignancies.
“The significance of disease monitoring in CML.”
“Is there anything left to debate in CML?”

U.C. San Diego. “Progression and Response in CML.”

National Cancer Care Network annual national meeting.
"NCCN guidelines for CML, 2008."
"New therapies in CML"

International Meeting on CML. Debate: "Second line TKI or transplantation in resistant CML?"

Canadian Bone Marrow Transplantation Group. "Transplantation for CML in the context of imatinib resistance."

MD Anderson Hematology Grand Rounds. "Resistance and progression in CML."

Korean Society of Hematology 50th Anniversary Conference Special Lecture. "Minimal residual diseas detection in leukemia."

National Cancer Care Network Congress. "Monitoring and treating progression in CML."

Stanford Transplantation Meeting, 2008. "The role of transplantation in CML."

Western Biotechnology and Bioinformatics Association Genomics Program. "Molecular treatment and diagnostics in CML."

Leukemia 2008, MD Anderson Cancer Center. "The role of transplantation in AML."

Turkey 45th Annual Oncology conference. "Early intervention for imatinib intolerance and resistance."

University of Miami Hematolgy/Oncology grand rounds. "Treatment, resistance, and progression in CML."

ASH symposium on high risk AML. "Use of minimal residual disease to identify high-risk patients."

2009

International Congress on Hematologic Malignancies.
"Non-myeloablative transplantation in older AML patients."
"Debate: Transplantation is the best option for AML in CR1. CON."

Global Opinion Leaders CML. "When to choose allogenic transplantation in CML."

NCCN National Meeting. "Molecular Markers in CML."